Bear lab (Bear 3rd from left, McCamphill on right)

Scientists Find a New Way to Reverse Symptoms of Fragile X

MIT Professor Mark Bear and colleagues have identified a new target for Fragile X therapeutics: GSK3 alpha. Several FRAXA research teams previously identified GSK3 beta as a treatment target.

Read More »

Mechanisms of Tolerance to Chronic mGluR5 Inhibition

FRAXA supported research showing mGluR5 antagonist tolerance develops quickly in Fragile X models, guiding new strategies to prevent or overcome it.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (38)